Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Total Non-Current Liabilities (2017 - 2026)

Corcept Therapeutics (CORT) has disclosed Total Non-Current Liabilities for 10 consecutive years, with $161.6 million as the latest value for Q1 2026.

  • For Q1 2026, Total Non-Current Liabilities rose 8.49% year-over-year to $161.6 million; the TTM value through Mar 2026 reached $161.6 million, up 8.49%, while the annual FY2025 figure was $173.7 million, 18.24% up from the prior year.
  • Total Non-Current Liabilities hit $161.6 million in Q1 2026 for Corcept Therapeutics, down from $173.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $177.6 million in Q3 2025 and bottomed at $49.1 million in Q2 2022.
  • Average Total Non-Current Liabilities over 5 years is $113.3 million, with a median of $106.4 million recorded in 2024.
  • Year-over-year, Total Non-Current Liabilities grew 8.05% in 2022 and then surged 129.65% in 2023.
  • Corcept Therapeutics' Total Non-Current Liabilities stood at $72.5 million in 2022, then skyrocketed by 44.16% to $104.5 million in 2023, then surged by 40.55% to $146.9 million in 2024, then increased by 18.24% to $173.7 million in 2025, then fell by 6.97% to $161.6 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $161.6 million, $173.7 million, and $177.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.